Ivor Elrifi Buys 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi acquired 237,616 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $237,616.00. Following the completion of the transaction, the chief executive officer directly owned 4,793,684 shares in the company, valued at $4,793,684. This represents a 5.22% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ivor Elrifi also recently made the following trade(s):

• On Tuesday, August 4th, Ivor Elrifi bought 83,807 shares of Tiziana Life Sciences stock. The stock was acquired at an average cost of $0.97 per share, with a total value of $81,292.79.
• On Monday, August 3rd, Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock. The stock was acquired at an average price of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Stock Up 2.6%

Shares of NASDAQ:TLSA opened at $1.00 on Friday. Tiziana Life Sciences Ltd has a 1 year low of $0.87 and a 1 year high of $2.53. The stock’s fifty day moving average price is $1.13 and its 200-day moving average price is $1.30.

Hedge Funds Weigh In On Tiziana Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of TLSA. Millennium Management LLC bought a new stake in shares of Tiziana Life Sciences in the third quarter worth $520,000. Jane Street Group LLC lifted its holdings in Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after acquiring an additional 151,858 shares during the period. Goldman Sachs Group Inc. boosted its position in Tiziana Life Sciences by 413.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock worth $164,000 after purchasing an additional 88,830 shares during the last quarter. Bison Wealth LLC bought a new stake in shares of Tiziana Life Sciences during the 4th quarter valued at about $30,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Tiziana Life Sciences during the 4th quarter valued at about $59,000.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Zacks Research raised Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Wall Street Zen downgraded shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Finally, Weiss Ratings lowered shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.